Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

Recruiting

EmpagliflozinEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

Sponsor:

Washington D.C. Veterans Affairs Medical Center

Code:

NCT06110130

Conditions

Chronic Kidney Diseases

Eligibility Criteria

Sex: All

Age: 19 - 70+

Healthy Volunteers: Not accepted

Interventions

Empagliflozin 10 MG

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Washington D.C. Veterans Affairs Medical Center on 2024-04-29.